SureClinical Launches Eclinical Ecosystem ECO Bundle
SureClinical announced the launch of their new Eclinical Ecosystem ECO Applications and Platform Bundle. The ECO Bundle connects people, programs, projects, and processes everywhere for a singular view of clinical data. The ECO Bundle centralizes clinical intelligence and reporting across multiple applications, data points and systems, allowing distributed clinical research teams to collaborate within a single, modern application experience.
The ECO bundle supports project management, document management, site management and quality management. With over 500 global clinical trials and multiple audits, and centralized documents and data in one repository, current SureClinical clients have the freedom to select and connect applications from multiple vendors, apps, and projects for quantifiable time-efficient delivery of new treatments and therapies.
The ECO bundle includes SureClinical’s SureCTMS, electronic Trial Master File (ETMF), Investigator Site File (ISF), Quality Management Software (QMS) and Clinical Trial Management (CTMS) applications. SureISF is a cloud-based regulatory document management solution.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
